Inactive Instrument

BELLUS Health Inc Stock price Toronto S.E.

Equities

CA07987C1059

Biotechnology & Medical Research

Sales 2021 16K 11.81K Sales 2022 16K 11.81K Capitalization 1.03B 763M
Net income 2021 -71M -52.39M Net income 2022 -76M -56.08M EV / Sales 2021 36,461 x
Net cash position 2021 248M 183M Net cash position 2022 336M 248M EV / Sales 2022 43,652 x
P/E ratio 2021
-8.96 x
P/E ratio 2022
-12.4 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 81.52%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 44 09-06-04
President - -
Chairman 77 01-12-31
Members of the board TitleAgeSince
Chairman 77 01-12-31
Director/Board Member 74 10-04-30
Director/Board Member 52 09-05-31
More insiders
BELLUS Health Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant is a highly selective antagonist of the P2X3 receptor, a clinically validated target to treat cough hypersensitivity. It is being evaluated in the CALM phase III clinical development programmed. It is developing camlipixant for the treatment of adults with RCC. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
More about the company
  1. Stock
  2. Equities
  3. Stock BELLUS Health
  4. Stock BELLUS Health Inc - Toronto S.E.